Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
View ORCID ProfileVincent Auvigne, View ORCID ProfileCynthia Tamandjou, View ORCID ProfileJustine Schaeffer, View ORCID ProfileSophie Vaux, Isabelle Parent du Chatelet
doi: https://doi.org/10.1101/2023.03.17.23287411
Vincent Auvigne
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Cynthia Tamandjou
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Justine Schaeffer
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Sophie Vaux
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Isabelle Parent du Chatelet
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France

- Supplementary material[supplements/287411_file02.pdf]
Posted March 18, 2023.
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Subject Area
Subject Areas
- Addiction Medicine (430)
- Allergy and Immunology (755)
- Anesthesia (221)
- Cardiovascular Medicine (3288)
- Dermatology (277)
- Emergency Medicine (479)
- Epidemiology (13359)
- Forensic Medicine (19)
- Gastroenterology (898)
- Genetic and Genomic Medicine (5147)
- Geriatric Medicine (481)
- Health Economics (782)
- Health Informatics (3264)
- Health Policy (1140)
- Hematology (429)
- HIV/AIDS (1017)
- Medical Education (476)
- Medical Ethics (127)
- Nephrology (522)
- Neurology (4919)
- Nursing (262)
- Nutrition (727)
- Oncology (2519)
- Ophthalmology (723)
- Orthopedics (280)
- Otolaryngology (347)
- Pain Medicine (323)
- Palliative Medicine (90)
- Pathology (543)
- Pediatrics (1299)
- Primary Care Research (556)
- Public and Global Health (7499)
- Radiology and Imaging (1704)
- Respiratory Medicine (980)
- Rheumatology (479)
- Sports Medicine (424)
- Surgery (547)
- Toxicology (72)
- Transplantation (235)
- Urology (205)